

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	A - Bio - Maria
Office Action Summary	Application No.	Applicant(s)
	10/522,865	BRUNS ET AL.
	Examiner	Art Unit
	Kahsay T. Habte	1624
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply		
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).		
Status		
1) Responsive to communication(s) filed on		
2a) ☐ This action is <b>FINAL</b> . 2b) ☐ This action is non-final.		
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is		
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.		
Disposition of Claims		
4) Claim(s) 1-14 is/are pending in the application.		
4a) Of the above claim(s) is/are withdrawn from consideration.		
5) Claim(s) is/are allowed.		
6)☐ Claim(s) is/are rejected.		
7) Claim(s) is/are objected to.		
8) Claim(s) <u>1-14</u> are subject to restriction and/or election requirement.		
Application Papers		
9)⊡ The specification is objected to by the Examiner.		
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.		
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).		
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).		
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.		
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).		
a) ☐ All b) ☐ Some * c) ☐ None of:		
1. Certified copies of the priority documents have been received.		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this National Stage		
application from the International Bureau (PCT Rule 17.2(a)).		
* See the attached detailed Office action for a list of the certified copies not received.		
·		·
Attachment(s)		
1) Notice of References Cited (PTO-892)	4) Interview Summary	(PTO-413)
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da	ate
Information Disclosure Statement(s) (PTO/SB/08)     Paper No(s)/Mail Date	5) Notice of Informat F 6) Other:	atent Application

Application/Control Number: 10/522,865

Art Unit: 1624

## **DETAILED ACTION**

1. Claims 1-14 are pending in this application.

## Election/Restrictions

2. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-14 (in part), drawn to monocyclic 1,3-thiazine compounds, process of making and method of use.

Group II, claim(s) 1-14 (in part), drawn to others e.g. polycyclic 1,3-thiazine compounds in which two substituents from the groups consisting of R<sup>2</sup> to R<sup>7</sup> with the C atoms forms a carbocyclic ring.

The inventions listed as Groups I-II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the special technical feature of Group I is a monocyclic 1,3-thazine compounds, process of making and method of use and is different from the special technical feature of Group II. The special technical feature of Group II is a polycyclic-1,3-thiazine compounds and this special feature is not present in Group I.

A telephone call was made to Nicanor Kohncke on 03/13/2008 to request an oral election to the above restriction requirement, but did not result in an election being made.

Application/Control Number: 10/522,865

Art Unit: 1624

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

It is recommended that applicants delete "use of" claims 7-8 and 13 and also delete claim 12. Applicants have also to delete a "method for preventing" from claim 14.

## Conclusion

Any inquiry concerning this communication or earlier communications from the 3. examiner should be directed to Kahsay Habte whose telephone number is (571) 272-0667. The examiner can normally be reached on M-F (9.00AM- 5:30PM).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached at (571) 272-0661. The fax phone number for the organization where this application or proceeding is assigned is (571)-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR.

Page 4

Application/Control Number: 10/522,865

Art Unit: 1624

Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Kahsay T. Habte/ Primary Examiner, Art Unit 1624

March 26, 2008

Organization IC1600 Bldg/Robre WSEN United States Patent and Trademark Office

P.O. Box 1450

Alexandria, VA 22313-1450

If Undeliverable Return in Ten Days

OFFICIAL BUSINESS PENALTY FOR PRIVATE USE, \$300

AN EQUAL OPPORTUNITY EMPLOYER



## RETURN TO SENDER Remove name from Mailing List - Employee

Bayer or not located at the Pittsburgh Site This individual is either no longer with